Reviews past records on immunotherapy for a rare cervical cancer
Looks back at records of people with rare cervical neuroendocrine carcinoma treated with immunotherapy.
Plain-language title generated from the registry record
Registry title: Immunotherapy in Neuroendocrine Carcinoma of the Cervix
Key facts
- Where
- Beijing, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 100 years old?
Source: NCT07911423, who can take part
Where in China
- Peking Union Medical College HospitalBeijing, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Peking Union Medical College Hospital
- Trial code
- NCT07911423
- Record updated
- 2 November 2026
- Original description
This retrospective study reviews existing medical records. No new treatments or tests are given. The study asks how well immunotherapy worked for people with a rare cancer called neuroendocrine carcinoma of the cervix. Immunotherapy is a treatment that helps the body's immune system fight cancer. The investigators will review the records of approximately 150 participants treated with immunotherapy for this cancer. The study will evaluate: (1) how long participants lived without the cancer getting worse; (2) how long participants lived overall; (3) whether the cancer shrank or stopped growing; (4) what side effects occurred, especially immune-related side effects; and (5) whether certain tumor markers or different treatment plans made a difference. Participants will not be contacted or asked to complete any procedures. Only information already contained in medical records will be used. Names and other personal details will be removed to protect privacy. The study has been approved by the ethics committee at Peking Union Medical College Hospital. The results may help doctors choose the best treatment for patients with this rare cancer. Results will be shared in medical journals and at medical meetings. For patients and families: This study does not enroll new participants. Questions about this cancer or immunotherapy should be directed to a physician.Read full original descriptionShow less
Efficacy of Immunotherapy in Neuroendocrine Carcinoma of the Cervix: A Retrospective Study
This retrospective study reviews existing medical records. No new treatments or tests are given. The study asks how well immunotherapy worked for people with a rare cancer called neuroendocrine carcinoma of the cervix. Immunotherapy is a treatment that helps the body's immune system fight cancer. The investigators will review the records of approximately 150 participants treated with immunotherapy for this cancer. The study will evaluate: (1) how long participants lived without the cancer getting worse; (2) how long participants lived overall; (3) whether the cancer shrank or stopped growing; (4) what side effects occurred, especially immune-related side effects; and (5) whether certain tumor markers or different treatment plans made a difference. Participants will not be contacted or asked to complete any procedures. Only information already contained in medical records will be used. Names and other personal details will be removed to protect privacy. The study has been approved by the ethics committee at Peking Union Medical College Hospital. The results may help doctors choose the best treatment for patients with this rare cancer. Results will be shared in medical journals and at medical meetings. For patients and families: This study does not enroll new participants. Questions about this cancer or immunotherapy should be directed to a physician.
Inclusion: Age ≥ 18 years at the time of diagnosis; Histopathologically confirmed diagnosis of neuroendocrine carcinoma of the cervix (NECC), including small cell type, large cell type, and mixed type; Received at least one cycle of immune checkpoint inhibitor-based therapy targeting the PD-1/PD-L1 pathway; Complete medical records, detailed treatment regimens, and available efficacy evaluation data.
Exclusion: Did not meet all of the above inclusion criteria; Key clinical data severely missing, making it impossible to extract valid informationinformation.